Case Details
- Citation: [2019] SGHC 86
- Court: High Court of the Republic of Singapore
- Decision Date: 29 March 2019
- Coram: Belinda Ang Saw Ean J
- Case Number: Suit No 1177 of 2016
- Hearing Date(s): 26, 27, 28 June 2018; 10 August 2018
- Claimant / Plaintiff: Cheong Chee Hwa
- Respondent / Defendant: China Star Food Group Ltd (formerly known as Brooke Asia Ltd)
- Counsel for Plaintiff: Foo Maw Shen, Ng Hui Min and Loh Chiu Kuan (Dentons Rodyk & Davidson LLP)
- Counsel for Respondent: Joseph Tay Weiwen and Chng Yan (Shook Lin & Bok LLP)
- Practice Areas: Contract; Interpretation of Contractual Documents; Reverse Takeovers
Summary
The judgment in Cheong Chee Hwa v China Star Food Group Ltd [2019] SGHC 86 addresses the complex intersection of private contractual obligations and public regulatory requirements within the context of a reverse takeover (RTO). The dispute arose following the RTO of Brooke Asia Limited (BAL) by China Star Food Holding Pte Ltd (CSFH), a transaction that resulted in the defendant being renamed China Star Food Group Ltd. The plaintiff, Mr. Cheong Chee Hwa, an investor who held a 1.62% stake in the defendant post-RTO, alleged that the defendant had breached express and implied contractual duties to ensure his shares were tradeable on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST) at a value that preserved his "potential upside."
Central to the litigation was the interpretation of a Sale and Purchase Agreement (SPA) dated 5 November 2014 and a subsequent Supplemental Agreement. Mr. Cheong contended that Clause 2.9 of the SPA imposed an absolute obligation on the defendant to place 101,000,000 shares at a minimum price of S$0.20 per share. He further argued that the defendant breached a "best commercial endeavours" warranty by implementing a share consolidation and subsequent placement at a price he characterized as a steep discount, which allegedly diluted the value of his investment. The defendant’s position was that no such absolute guarantee existed and that the corporate actions taken—including the share consolidation—were necessary to comply with the mandatory requirements of the Catalist Rules for re-listing.
Justice Belinda Ang Saw Ean dismissed the plaintiff’s claims in their entirety. The Court held that the contractual documents, when interpreted through the lens of the objective "commercial common sense" approach, did not support the existence of an absolute obligation to issue a fixed number of shares at a specific price. The Court emphasized that the "best commercial endeavours" obligation did not equate to a guarantee of a specific market outcome or share price. Instead, the defendant’s actions were found to be commercially reasonable and driven by the necessity of meeting SGX-ST’s regulatory standards for the resumption of trading.
This decision provides critical guidance for practitioners on the limits of implied terms in sophisticated commercial contracts. It reinforces the principle that courts will not readily imply terms that shift the commercial risk of a transaction from an investor to a company, especially where the alleged terms contradict the express regulatory framework governing the transaction. The judgment also clarifies the standard of effort required under a "best commercial endeavours" clause in the context of corporate finance and regulatory compliance.
Timeline of Events
- 31 March 2014: BAL becomes a "cash company" under Rule 1017 of the SGX-ST Catalist Rules, leading to a suspension of its shares from trading.
- 5 November 2014: BAL enters into a Sale and Purchase Agreement (the “SPA”) with the original shareholders of CSFH to acquire the entire issued share capital of CSFH for S$168,000,000.
- 16 April 2015: A Supplemental Agreement is entered into between the parties to the SPA.
- 26 June 2015: The SGX-ST issues a listing-quote letter regarding the RTO.
- 6 July 2015: BAL issues a circular to shareholders regarding the proposed RTO and share consolidation.
- 20 July 2015: Shareholders of BAL approve the RTO and the consolidation of every four existing shares into one consolidated share.
- 21 July 2015: Completion of the SPA occurs. BAL is renamed China Star Food Group Ltd.
- 15 September 2015: The defendant announces a proposed compliance placement to meet the Catalist shareholding spread requirements.
- 22 September 2015: The defendant enters into a placement agreement for the issuance of consolidated placement shares.
- 18 November 2015: The defendant announces the completion of the compliance placement of 16,475,665 consolidated shares at S$0.33 per share.
- 26 November 2015: Trading in the defendant’s shares resumes on the Catalist board.
- 29 July 2016: Mr. Cheong Chee Hwa commences Suit No 1177 of 2016 against the defendant.
- 26–28 June 2018: Substantive hearing of the trial before Justice Belinda Ang Saw Ean.
- 10 August 2018: Final day of the substantive hearing.
- 29 March 2019: The High Court delivers its judgment, dismissing the plaintiff's action.
What Were the Facts of This Case?
The dispute centered on the reverse takeover of Brooke Asia Limited (BAL), a company listed on the Catalist board of the SGX-ST, by China Star Food Holding Pte Ltd (CSFH). Prior to the RTO, BAL had become a "cash company" under Rule 1017 of the Catalist Rules, meaning its assets consisted wholly or substantially of cash. Consequently, trading in BAL’s shares was suspended, and the company faced potential de-listing unless it could acquire a viable operating business. CSFH, the target, was involved in the production and sale of sweet potato snack food products in the People's Republic of China.
On 5 November 2014, BAL entered into a Sale and Purchase Agreement (SPA) with the original shareholders of CSFH. Under the terms of the SPA, BAL agreed to acquire CSFH for a total consideration of S$168,000,000. This consideration was to be satisfied by the issuance and allotment of 840,000,000 new shares (the “Consideration Shares”) at an "Issue Price" defined in Clause 1.1 as S$0.20 per share. The transaction also involved the issuance of "Arranger Shares" (27,500,000 shares) and "PPCF Shares" (3,500,000 shares) to various advisors and sponsors.
The plaintiff, Mr. Cheong Chee Hwa, was not an original party to the SPA but became a shareholder of the defendant post-RTO. He held 4,158,000 shares, representing approximately 1.62% of the issued share capital, following an investment of S$2,000,000. Mr. Cheong’s case was built on the premise that the RTO was intended to result in a "handsome return" on his investment once the shares resumed trading. He alleged that the defendant had a contractual obligation to ensure that the shares were tradeable at a price that reflected the S$0.20 issue price, adjusted for any corporate actions like share consolidation.
A critical component of the RTO was the "Compliance Placement" required by the Catalist Rules. To maintain its listing, the defendant had to ensure a minimum public float—specifically, that at least 15% of the enlarged share capital was held by at least 200 public shareholders. Clause 2.9 of the SPA addressed this, stating that if the shareholding spread was not met upon completion, the defendant would place out such number of new shares as required, provided the issue price for these placement shares was not less than the S$0.20 Issue Price.
However, the RTO process also involved a share consolidation. On 20 July 2015, shareholders approved the consolidation of every four existing shares into one consolidated share. This meant the theoretical "Issue Price" of S$0.20 for a pre-consolidation share would correspond to S$0.80 for a consolidated share. When the defendant eventually conducted its compliance placement in November 2015, it issued 16,475,665 consolidated shares at a price of S$0.33 per share. Mr. Cheong argued that this price represented a significant discount to the S$0.80 "floor" he believed was mandated by the SPA, thereby diluting his stake and breaching the defendant's obligations.
The defendant, led by its Chairman and CEO, Mr. Liang Cheng Wang, contended that the share consolidation and the placement price were necessary commercial decisions. The defendant argued that the market conditions and the requirements of the SGX-ST dictated the terms of the placement. They maintained that Clause 2.9 did not create a fixed obligation to issue 101,000,000 shares (as the plaintiff calculated based on a 15% float of the pre-consolidation capital) but rather a mechanism to achieve regulatory compliance. The defendant also relied on the fact that the SGX-ST had approved the resumption of trading following these actions, suggesting that the regulatory requirements had been satisfied.
What Were the Key Legal Issues?
The primary legal issue was one of contractual interpretation: whether the SPA and the Supplemental Agreement imposed an express or implied obligation on the defendant to re-list BAL in a specific manner that guaranteed the tradeability and value of the plaintiff's shares. This required the Court to determine if the "Issue Price" of S$0.20 served as a mandatory price floor for all subsequent share issuances, regardless of intervening corporate actions like share consolidation.
The second issue concerned the implication of terms. The plaintiff sought to imply a term that the defendant was required to re-list the company such that the plaintiff’s shares would be "freely tradeable" and that the defendant would not take any action to "undermine the potential upside" of the plaintiff’s investment. The Court had to apply the business efficacy and officious bystander tests to determine if such terms were necessary to give effect to the parties' intentions.
The third issue was whether the defendant had breached the "best commercial endeavours" warranty found in the SPA. This warranty required the defendant to use its best efforts to ensure the Consideration Shares, PPCF Shares, and Arranger Shares were listed and admitted for trading. The legal question was whether the defendant’s decision to consolidate shares and conduct the placement at S$0.33 per consolidated share (instead of S$0.80) constituted a failure to exercise the required level of endeavour.
Finally, the Court had to address the regulatory overlay of the Catalist Rules. Specifically, whether the defendant's compliance with Rule 1017 and the shareholding spread requirements (Rule 406(1) and Rule 1015(3)) provided a complete defense to the plaintiff’s claims of contractual breach, or whether the contract imposed higher standards than the minimum regulatory requirements.
How Did the Court Analyse the Issues?
The Court’s analysis began with the fundamental principles of contractual interpretation. Justice Belinda Ang Saw Ean applied the framework established in Zurich Insurance (Singapore) Pte Ltd v B-Gold Interior Design & Construction Pte Ltd [2008] 3 SLR(R) 1029 and Sembcorp Marine Ltd v PPL Holdings Pte Ltd [2013] 4 SLR 193. The Court emphasized that the process of interpretation involves ascribing meaning to the words used by the parties in the context of the agreement as a whole and the relevant commercial background.
Regarding the alleged express obligation under Clause 2.9 of the SPA, the Court scrutinized the text:
"In the event that the shareholding spread and distribution requirements of the SGX-ST ... are not met ... the Company shall ... place out such number of new Shares ... as may be required ... provided that the issue price for such new Shares shall not be less than the Issue Price." (at [8])
The Court rejected the plaintiff’s argument that this clause mandated the placement of exactly 101,000,000 shares at S$0.20. The Court found that the "Issue Price" of S$0.20 was a benchmark for the RTO transaction itself—specifically for valuing the CSFH business at S$168 million—and was not intended to be an immutable floor for all future capital raises. The Court noted that the phrase "as may be required" linked the obligation directly to the prevailing regulatory requirements of the SGX-ST at the time of the placement, rather than a fixed historical number.
On the issue of implied terms, the Court applied the three-step test from Sembcorp Marine. The Court found that there was no "gap" in the contract that required filling. The SPA already contained detailed provisions regarding the RTO and the compliance placement. Furthermore, the Court held that the plaintiff’s proposed implied terms—guaranteeing share value and tradeability—failed both the business efficacy and officious bystander tests. The Court reasoned that it was not necessary for the business efficacy of the SPA to guarantee a specific market price for the shares post-RTO. Such a term would also not have been agreed upon by the parties at the outset, as it would expose the company to market risks beyond its control. The Court observed that investors in RTOs inherently bear the risk of market fluctuations and regulatory changes.
The analysis of the "best commercial endeavours" warranty was particularly deep. The Court referred to KS Energy Services Ltd v BR Energy (M) Sdn Bhd [2014] 2 SLR 905, which sets out the guidelines for such clauses. The Court noted that "best commercial endeavours" does not mean an absolute obligation to achieve a result, but rather an obligation to take all reasonable steps that a prudent and determined businessperson would take. The Court found that the defendant had indeed exercised such endeavours. The decision to consolidate shares was a commercial necessity to meet the SGX-ST’s minimum bid price requirements and to make the company more attractive to institutional investors during the placement. The Court stated:
"I find that there is no absolute obligation that China Star has to place 101,000,000 shares at a price of S$0.20 under cl 2.9 of the SPA" (at [60])
The Court further reasoned that the defendant’s primary objective under the "best commercial endeavours" clause was to achieve the re-listing and resumption of trading. The fact that trading did resume on 26 November 2015 was strong evidence that the defendant had successfully fulfilled its core obligation. The plaintiff’s complaint was essentially about the price at which the re-listing was achieved, but the Court held that the "best commercial endeavours" clause did not extend to guaranteeing a specific share price or preventing dilution that was necessary for regulatory compliance.
The Court also addressed the plaintiff’s argument regarding the "steep discount" of the S$0.33 placement price. The Court reviewed the Notes of Evidence (NE) from 27 June 2018 and the testimony of Mr. Liang. It found that the placement price was determined by market demand and the advice of the defendant’s placement agents. There was no evidence that the defendant acted in bad faith or failed to seek the best possible price. The Court concluded that the defendant’s actions were a "commercially necessary" response to the regulatory and market environment.
What Was the Outcome?
The High Court dismissed the plaintiff’s claim in its entirety. Justice Belinda Ang Saw Ean found that the plaintiff had failed to establish any breach of the SPA or the Supplemental Agreement. Specifically, the Court ruled that the defendant was not under an absolute contractual obligation to issue a fixed number of shares at a specific price floor, nor had it breached its "best commercial endeavours" obligation by proceeding with the share consolidation and the compliance placement at S$0.33 per consolidated share.
The operative conclusion of the judgment was stated as follows:
"Accordingly, the action is dismissed. China Star shall have the costs of the action, to be taxed if not agreed." (at [95])
The Court ordered that the plaintiff pay the defendant’s costs on a standard basis. In reaching this conclusion, the Court emphasized that the plaintiff’s investment loss was a result of market forces and the inherent risks of participating in a reverse takeover, rather than any actionable breach of contract by the defendant. The Court noted that the defendant had successfully navigated the "cash company" status and achieved a resumption of trading, which was the primary commercial objective of the RTO framework.
The judgment also effectively validated the defendant's use of share consolidation as a tool for regulatory compliance. By dismissing the claim that consolidation breached the "Issue Price" floor, the Court affirmed that corporate actions taken to satisfy listing requirements (such as the Catalist Rules) are generally consistent with "best commercial endeavours" unless the contract explicitly prohibits them or they are performed in bad faith.
Why Does This Case Matter?
Cheong Chee Hwa v China Star Food Group Ltd is a significant precedent for corporate and commercial practitioners in Singapore, particularly those involved in RTOs, IPOs, and capital markets. Its importance lies in three main areas: the interpretation of "best commercial endeavours" in a regulatory context, the limits of implied terms in investment disputes, and the judicial approach to share price guarantees.
First, the case clarifies the standard of "best commercial endeavours" within the framework of SGX-ST listing requirements. Practitioners often include such clauses to provide comfort that a company will seek to achieve a listing. This judgment confirms that such a clause is an obligation of means, not result. As long as a company takes reasonable, prudent, and commercially sound steps to achieve the listing—even if those steps involve share consolidation or placements at prices lower than an investor might hope—it is unlikely to be in breach. The Court’s reliance on KS Energy reinforces that "best endeavours" must be viewed through the lens of what is commercially feasible.
Second, the judgment serves as a warning against the "implied term" trap. Investors who suffer losses often attempt to read into contracts guarantees of value or tradeability that are not expressly stated. The Court’s rigorous application of the Sembcorp Marine test demonstrates that in sophisticated commercial transactions, the written word is paramount. The Court will not use implied terms to protect an investor from the downside of a risky corporate maneuver like an RTO. If an investor wants a price floor or a non-dilution guarantee, it must be explicitly drafted into the contract.
Third, the case highlights the tension between private contract law and public regulatory compliance. The defendant was caught between a potential contractual interpretation (the S$0.20 floor) and the practical reality of satisfying the SGX-ST’s requirements for a minimum bid price and public float. The Court’s decision to prioritize the "commercially necessary" actions taken to satisfy the regulator suggests that, in the absence of clear language to the contrary, courts will interpret commercial contracts in a way that allows companies to comply with mandatory regulatory standards.
Finally, for practitioners drafting RTO documentation, the case emphasizes the need for precision in defining terms like "Issue Price." If a price is intended to be a floor for all future placements, the contract must say so explicitly and address how that floor interacts with corporate actions like consolidations or rights issues. Without such clarity, the "Issue Price" may be viewed merely as a valuation benchmark for the acquisition itself, rather than a continuing obligation to shareholders.
Practice Pointers
- Drafting Price Floors: When defining an "Issue Price" in an RTO or SPA, explicitly state whether this price is intended to act as a minimum floor for future compliance placements or subsequent capital raises.
- Addressing Corporate Actions: Ensure that any price-related obligations include adjustment clauses for share consolidations, sub-divisions, or rights issues to avoid disputes over "theoretical" vs. "actual" prices.
- Defining "Best Endeavours": If a client requires a specific outcome (e.g., a listing at a specific valuation), avoid "best commercial endeavours" and instead use "absolute obligation" or "condition precedent" language, though this may be difficult to negotiate.
- Managing Investor Expectations: For companies, ensure that circulars and disclosure documents clearly state that re-listing is subject to regulatory approval and market conditions, and that no specific share price is guaranteed.
- Regulatory Compliance as a Shield: In litigation, emphasize that actions taken were "commercially necessary" to satisfy mandatory regulatory requirements (e.g., Catalist Rules), as courts are reluctant to find breaches for actions required by a regulator.
- Implied Terms Strategy: When representing investors, recognize that the "gap" required for an implied term is difficult to find in a 60-page SPA. Focus instead on express warranties or misrepresentation if the facts support them.
- Evidence of Market Conditions: Maintain a clear record of advice from placement agents and sponsors regarding market demand and pricing to defend against claims that a placement was conducted at an "unreasonable" discount.
Subsequent Treatment
The High Court's decision in [2019] SGHC 86 was appealed by Mr. Cheong Chee Hwa to the Court of Appeal in Civil Appeal No 92 of 2019. The Court of Appeal dismissed the appeal on 19 February 2019 without issuing further written grounds, indicating that it found the High Court's reasoning persuasive and saw no reason to depart from the findings. The ratio regarding the interpretation of "best commercial endeavours" in the context of regulatory necessity remains a stable point of reference in Singapore contract law, particularly for corporate finance disputes involving the SGX-ST.
Legislation Referenced
- SGX-ST Catalist Rules: Rule 1017 (Cash Companies); Rule 406(1) (Shareholding Spread); Rule 1015(3) (Admission Requirements for RTOs); Part VIII (Admission Standards).
- Companies Act (Cap 50): Referenced in relation to the corporate actions and share issuances.
Cases Cited
- Zurich Insurance (Singapore) Pte Ltd v B-Gold Interior Design & Construction Pte Ltd [2008] 3 SLR(R) 1029 (Applied)
- Sembcorp Marine Ltd v PPL Holdings Pte Ltd and another and another appeal [2013] 4 SLR 193 (Followed)
- KS Energy Services Ltd v BR Energy (M) Sdn Bhd [2014] 2 SLR 905 (Followed)
- Lim Sze Eng v Lin Choo Mee [2019] 1 SLR 414 (Referred to)
- PT Bayan Resources TBK and another v BCBC Singapore Pte Ltd and another [2019] 1 SLR 30 (Referred to)
- Lucky Homes Pte Ltd (formerly known as Diamond Kendall Ltd) v Ong Puay Koon and others and another appeal [2018] 1 SLR 170 (Referred to)